Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.BTG Initiates Phase IIa Pleneva Study
The study conducted in 166 patients with the relapsing-remitting (RRMS) form of the disease, comprises an initial 24 week double-blind, placebo-controlled dosing period followed by a 24 week
The study conducted in 166 patients with the relapsing-remitting (RRMS) form of the disease, comprises an initial 24 week double-blind, placebo-controlled dosing period followed by a 24 week
Fortis-M is a global, multicenter, randomised, double-blind, placebo-controlled phase 3 trial. It evaluates oral Talactoferrin plus best supportive care compared to placebo, plus best supportive care in patients
Jean-Michel Halfon, president of emerging-markets business at Pfizer, said that the drug maker intends to increase its sales force from 2,300 in approxiamtely 180 cities to about 3,200
The companies said that the agreement is expected to provide researchers in the Asian market access to quality modified nucleic acid products, to further advance research efforts in
The patent entitled ‘Sustained-Release Bupropion and Bupropion/Mecamylamine Tablets’ discloses the formulation of pharmaceutical tablets containing sustained-release granules of bupropion HCl distributed in a sustained-release matrix. Horst Zerbe, president
The company said that the trial 03-113 was a six-week, randomised, placebo-controlled trial in 490 patients, who had a fluorescein staining score of three in the central region
In addition, the parties have executed a contract manufacturing services agreement under which BioLife will manufacture OriGen’s DMSO and DMSO/Dextran cryopreservation media products under sterile GMP conditions into
The company claims that the increased capacity is of particular benefit to high throughput laboratories, extending processing time and increasing laboratory productivity. Concentrated reagent wedges liberate space on
The company said that the facility has been designed for the supply of late-phase clinical trial tablet and capsule products, and will be capable of handling batch sizes
GAI-122 is being developed as IV administered formulation of an intracellular neuro-protectant that employs AlphaRx’s proprietary nano-emulsion formulation technology. More specifically, GAI-122 is being developed for the amelioration